Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Historic Non-Current Deffered Revenue for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2022 value amounting to $6.6 million.

  • Xeris Biopharma Holdings' Non-Current Deffered Revenue fell 265.16% to $6.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $6.6 million, marking a year-over-year decrease of 265.16%. This contributed to the annual value of $6.9 million for FY2021, which is 383.16% up from last year.
  • Xeris Biopharma Holdings' Non-Current Deffered Revenue amounted to $6.6 million in Q3 2022, which was down 265.16% from $6.8 million recorded in Q2 2022.
  • In the past 5 years, Xeris Biopharma Holdings' Non-Current Deffered Revenue ranged from a high of $6.9 million in Q1 2022 and a low of $6.6 million during Q4 2020
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $6.8 million (2021), whereas its average is $6.8 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Non-Current Deffered Revenue soared by 383.16% in 2021, and later plummeted by 265.16% in 2022.
  • Over the past 3 years, Xeris Biopharma Holdings' Non-Current Deffered Revenue (Quarter) stood at $6.6 million in 2020, then rose by 3.83% to $6.9 million in 2021, then dropped by 3.46% to $6.6 million in 2022.
  • Its Non-Current Deffered Revenue was $6.6 million in Q3 2022, compared to $6.8 million in Q2 2022 and $6.9 million in Q1 2022.